{"id":"W4241454646","doi":"10.3747/co.v18is2.958","title":"Progression-Free Survival as a Clinical Trial Endpoint in Advanced Renal Cell Carcinoma","year":2011,"lang":"en","type":"article","venue":"Current Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; University of Toronto; Western University; Centre Hospitalier de l’Université de Montréal; University Health Network; Ottawa Hospital; Ottawa Regional Cancer Foundation; University of Ottawa; BC Cancer Agency; Princess Margaret Cancer Centre; St. Michael's Hospital; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Clinical trial; Renal cell carcinoma; Intensive care medicine; Progression-free survival; Oncology; Endpoint Determination; Overall survival; Disease; Surrogate endpoint; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.285654,0.0005021507,0.002022113,0.001766985,0.0006305454,0.003224707,0.000930723,0.002461706,0.001210926],"category_scores_gemma":[0.352963,0.0002419914,0.002130122,0.003375513,0.002839566,0.002504466,0.002172207,0.002807145,0.0001714505],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00261102,"about_ca_system_score_gemma":0.004328973,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007505442,"about_ca_topic_score_gemma":0.0009479992,"domain_scores_codex":[0.608303,0.3744061,0.009599162,0.001372651,0.005588611,0.0007304102],"domain_scores_gemma":[0.5990049,0.3467571,0.03756314,0.007303534,0.006577877,0.002793413],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.067268,0.001661864,0.1548651,0.01501226,0.009459644,0.001133346,0.002722398,0.04777014,0.001218015,0.2178598,0.0169119,0.4641175],"study_design_scores_gemma":[0.03289413,0.0407446,0.1899994,0.02050613,0.007923923,0.002143642,0.002153751,0.1697474,0.005497717,0.4379225,0.08969285,0.0007738877],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5190042,0.1932641,0.1444323,0.08914939,0.004166122,0.00921477,0.002107831,0.0001466086,0.03851468],"genre_scores_gemma":[0.9608298,0.009807633,0.01974776,0.003969079,0.0009320734,0.003370617,0.0003150337,0.00002764562,0.001000222],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.285654,"threshold_uncertainty_score":0.8809158,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.7607084304829609,"score_gpt":0.579968775289633,"score_spread":0.1807396551933279,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}